TABLE 2.
Relative risk ratios of treatment regimen differences for the risk of pruritus and rash.
| Treatment scheme | No. of trials | Any-grade pruritus | No. of trials | Any-grade rash | No. of trials | 3–5 grade pruritus | No. of trials | 3–5 grade rash | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95%CI) | p | RR (95%CI) | p | RR (95%CI) | RR (95%CI) | RR (95%CI) | p | |||||
| A:PD-1/L1+chemotherapyVS chemotherapy | 4 | 1.39 (1.08, 1.80) | 0.01 | 5 | 1.53 (1.19, 1.98) | 0.001 | 4 | NA | NA | 5 | 2.64 (0.82, 4.16) | 0.15 |
| B: PD-1/L1 VS chemotherapy | 13 | 4.67 (3.66, 5.95) | <0.00001 | 12 | 1.82 (1.52, 2.19) | <0.00001 | 13 | 0.86 (0.28, 2.66) | 0.43 | 12 | 1.85 (0.54, 2.57) | 0.69 |
| RRR (A VS B) | — | 0.30 (0.21, 0.42) | <0.00001 | RRR (A VS B) | 0.84 (0.61, 1.15) | 0.28 | — | NA | NA | RRR (A VS B) | 1.43 (0.46, 4.40) | 0.54 |
| Treatment scheme | No. of trials | Any-grade pruritus | No. of trials | Any-grade rash | No. of trials | 3–5 grade pruritus | No. of trials | 3–5 grade rash | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95%CI) | p | RR (95%CI) | p | RR (95%CI) | RR (95%CI) | RR (95%CI) | p | |||||
| C: PD-1/L1+chemotherapy VS chemotherapy | 3 | 1.39 (1.08, 1.80) | 0.01 | 3 | 1.53 (1.19, 1.98) | 0.001 | 3 | NA | NA | 3 | 2.64 (0.71, 9.88) | 0.15 |
| D: CTLA-4+chemotherapy VS chemotherapy | 14 | 6.31 (4.40, 9.04) | <0.00001 | 14 | 5.32 (3.90, 7.28) | <0.00001 | 14 | 7.92 (1.86, 33.65) | 0.005 | 14 | 10.11 (2.47, 41.41) | 0.001 |
| RRR (C VS D) | — | 0.22 (0.14, 0.49) | <0.00001 | RRR (C VS D) | 0.29 (0.19, 0.43) | <0.00001 | — | NA | NA | RRR (C VS D) | 0.25 (0.04, 1.73) | 0.08 |